To facilitate clinical trials, non-invasive PET/CT may be a great tool for monitoring NRF2 activity and the therapeutic response in NRF2high ESCC, and thus it warrants further clinical studies. This evidence concerns the gene NFE2L2 and esophageal squamous cell carcinoma.